Taro Pharmaceutical Industries Limited

Stock Symbol: 
Case Status: 

Ademi LLP is investigating Taro (NYSE: TARO) for possible breaches of fiduciary duty and other violations of law in its transaction with its majority shareholder Sun.

In the transaction, Taro’s stockholders receive $43.00 in cash for each share of Taro common stock they own. Taro insiders receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Taro’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.